Learn About Ingrezza and Huntington Disease Chorea Treatment

Huntington disease is a hereditary neurodegenerative disorder that can affect movement, thinking, mood, and behavior. Chorea is one of its commonly recognized movement symptoms and involves involuntary, irregular, and unpredictable movements. Ingrezza contains valbenazine and is FDA approved for treating chorea associated with Huntington disease in adults. It is a VMAT2 inhibitor that influences the storage and release of certain neurotransmitters involved in movement control.

Understanding Ingrezza and Huntington Disease Chorea

Ingrezza is available as oral capsules and Ingrezza Sprinkle capsules. For adults with Huntington disease chorea, the FDA prescribing information lists an initial dose of 40 mg once daily. The dose may be increased by 20 mg every two weeks according to response and tolerability, with 80 mg once daily listed as the recommended dose. Lower doses of 40 mg or 60 mg may be considered depending on the individual situation.

Important points about its use include:

• Ingrezza is approved for adults with chorea associated with Huntington disease.
• It may be taken with or without food.
• Dosing should be determined and adjusted by the prescribing healthcare professional.
• Certain liver conditions and genetic differences affecting CYP2D6 metabolism may require a lower dose.
• Some medications can interact with valbenazine and may require dose adjustments or avoidance.

Ingrezza is intended to help manage chorea symptoms rather than cure Huntington disease. Treatment decisions generally consider the severity of movements, overall health, other medicines, and the person's response to treatment.

Safety Considerations and Monitoring During Treatment

Like other prescription medicines, Ingrezza can cause side effects and requires appropriate medical supervision. The FDA prescribing information includes a boxed warning concerning an increased risk of depression and suicidal thoughts or behavior in people with Huntington disease. Patients, caregivers, and families should promptly report new or worsening depression, suicidal thoughts, or unusual behavioral changes to the treating healthcare professional.

Other important safety considerations include:

• Sleepiness, sedation, or lethargy may occur and can affect activities requiring alertness.
• QT interval prolongation can occur, so relevant heart conditions and medications should be considered.
• Hypersensitivity reactions, including angioedema, are possible.
• Parkinson like symptoms have been reported and may require dose reduction or discontinuation.
• Neuroleptic malignant syndrome is a rare but serious reaction requiring medical attention.
• Reported adverse reactions in people treated for Huntington disease chorea include somnolence, lethargy or sedation, rash, urticaria, and insomnia.

Regular follow-up allows healthcare professionals to assess whether chorea symptoms are responding to treatment and whether side effects or changes in mood, behavior, movement, or other health conditions require attention. Medication decisions should always be individualized rather than based solely on information from general sources.

Ingrezza or valbenazine is an FDA approved VMAT2 inhibitor for treating chorea associated with Huntington disease in adults. Understanding its purpose, dosing approach, potential adverse effects, and important warnings can help patients and caregivers discuss treatment options with their healthcare professionals. This information is educational only and is not intended to provide medical diagnosis, treatment, sales, or healthcare services.